•Reviewing and understanding the drivers of on and off target ADC toxicities
•Understanding best practices to minimise the translational mismatch observed with ADC toxicity characterisation
•Leveraging learnings to mitigate clinical toxicity and maximise ADC therapeutic index
Moderator: Joost Uitdehaag, Head of Biology, Crossfire Oncology
Panellists:
Xiaona Jing, Chief Executive Officer & CoFounder, ClearideBio Therapeutics
Gokhan Yahioglu, Co-Founder & Director of Chemistry, Antikor Biopharma
